<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00049244</url>
  </required_header>
  <id_info>
    <org_study_id>BMS-CA163-031</org_study_id>
    <secondary_id>UCLA-0206011</secondary_id>
    <secondary_id>CDR0000258052</secondary_id>
    <secondary_id>NCI-G02-2120</secondary_id>
    <nct_id>NCT00049244</nct_id>
  </id_info>
  <brief_title>BMS-247550 Plus Capecitabine in Treating Patients With Metastatic Breast Cancer</brief_title>
  <official_title>A Phase I Study of BMS-247550 in Combination With Capecitabine in Patients With Metastatic Breast Cancer Previously Treated With a Taxane and an Anthracycline</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>R-Pharm</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>R-Pharm</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so&#xD;
      they stop growing or die. Combining more than one drug may kill more tumor cells.&#xD;
&#xD;
      PURPOSE: Phase I trial to study the effectiveness of combining BMS-247550 with capecitabine&#xD;
      in treating patients who have metastatic breast cancer that has not responded to previous&#xD;
      chemotherapy with a taxane and an anthracycline.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the maximum tolerated dose of BMS-247550 and capecitabine, on 2 different&#xD;
           schedules, in patients with metastatic breast cancer previously treated with a taxane&#xD;
           and an anthracycline.&#xD;
&#xD;
        -  Determine the safety profile of this regimen in these patients.&#xD;
&#xD;
        -  Determine, preliminarily, any antitumor activity of this regimen in these patients.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study. Patients are assigned to 1 of 2 groups.&#xD;
&#xD;
        -  Group I: Patients receive BMS-247550 IV over 3 hours on day 1 and oral capecitabine&#xD;
           twice daily on days 1-14.&#xD;
&#xD;
        -  Group II: Patients receive BMS-247550 IV over 1 hour on days 1-3 and capecitabine as in&#xD;
           group I.&#xD;
&#xD;
      Treatment in both groups repeats every 3 weeks for 2-18 courses in the absence of disease&#xD;
      progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 6 patients receive escalating doses of BMS-247550 and capecitabine until the&#xD;
      maximum tolerated dose (MTD) is determined for each group. The MTD is defined as the dose at&#xD;
      which no more than 1 of 6 patients experiences dose-limiting toxicity. Additional patients&#xD;
      are treated at the MTD.&#xD;
&#xD;
      Patients are followed for at least 30 days and then every 3 months thereafter.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 34-60 patients will be accrued for this study within 8-12&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>September 2002</start_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>capecitabine</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ixabepilone</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed breast cancer&#xD;
&#xD;
               -  Metastatic disease by radiography or histology&#xD;
&#xD;
          -  Must have received prior chemotherapy with a taxane and an anthracycline in the&#xD;
             adjuvant or metastatic setting&#xD;
&#xD;
               -  No more than 2 prior chemotherapy regimens in the metastatic setting&#xD;
&#xD;
          -  Measurable or evaluable disease&#xD;
&#xD;
               -  Bone lesions not measurable&#xD;
&#xD;
               -  Primary breast lesions not measurable if assessed only by physical exam&#xD;
&#xD;
          -  No active brain metastasis&#xD;
&#xD;
               -  No cerebral edema by CT scan or MRI&#xD;
&#xD;
               -  No progression since prior imaging studies&#xD;
&#xD;
               -  No requirement for steroids&#xD;
&#xD;
               -  No clinical symptoms of brain metastasis&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 3 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Absolute neutrophil count at least 2,000/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 9.0 g/dL&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 times upper limit of normal (ULN)&#xD;
&#xD;
          -  ALT no greater than 2.5 times ULN&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine less than 1.5 times ULN&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  No uncontrolled or significant cardiovascular disease&#xD;
&#xD;
          -  No myocardial infarction within the past year&#xD;
&#xD;
          -  No uncontrolled angina within the past year&#xD;
&#xD;
          -  No history of congestive heart failure&#xD;
&#xD;
          -  No history of atrial or ventricular arrhythmias&#xD;
&#xD;
          -  No history of second- or third-degree heart block&#xD;
&#xD;
          -  No uncontrolled hypertension&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  No hypersensitivity to Cremophor EL or fluorouracil&#xD;
&#xD;
          -  No prior intolerance to fluoropyrimidines&#xD;
&#xD;
          -  No other serious uncontrolled medical disorder or active infection that would preclude&#xD;
             study&#xD;
&#xD;
          -  No dementia or altered mental status that would preclude study&#xD;
&#xD;
          -  No grade 2 or greater neuropathy (neuromotor or neurosensory)&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Chemotherapy&#xD;
&#xD;
          -  Prior immunotherapy allowed&#xD;
&#xD;
          -  No concurrent trastuzumab (Herceptin)&#xD;
&#xD;
          -  No concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas, mitomycin, or&#xD;
             doxorubicin HCl liposome)&#xD;
&#xD;
          -  At least 2 years since prior high-dose chemotherapy with bone marrow transplantation&#xD;
             or peripheral blood stem cell support&#xD;
&#xD;
          -  No prior epothilone, capecitabine, or continuous-infusion fluorouracil&#xD;
&#xD;
          -  No other concurrent chemotherapy&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Prior hormonal therapy allowed&#xD;
&#xD;
          -  No concurrent hormonal therapy&#xD;
&#xD;
          -  Concurrent hormone replacement therapy allowed&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  At least 3 weeks since prior radiotherapy&#xD;
&#xD;
          -  No prior radiotherapy to more than 25% of the bone marrow&#xD;
&#xD;
          -  No concurrent therapeutic radiotherapy&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  At least 3 weeks since prior investigational cytotoxic agents&#xD;
&#xD;
          -  No concurrent warfarin for therapeutic anticoagulation&#xD;
&#xD;
               -  Low-dose warfarin allowed for implanted ports or indwelling catheters&#xD;
&#xD;
          -  No other concurrent experimental anticancer medications&#xD;
&#xD;
          -  No other concurrent antitumor therapy&#xD;
&#xD;
          -  Concurrent bisphosphonates for palliation of bone metastases allowed if initiated&#xD;
             before study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linnea Chap, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>November 12, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 27, 2017</last_update_submitted>
  <last_update_submitted_qc>January 27, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2017</last_update_posted>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

